
Ask a doctor about a prescription for MONTELUKAST AUROVITAS 10 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Montelukast Aurovitas 10 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
5. Storage of Montelukast Aurovitas
6. Contents of the Pack and Further Information
What is Montelukast Aurovitas
Montelukast is a leukotriene receptor antagonist that blocks substances called leukotrienes.
How Montelukast Aurovitas Works
Leukotrienes cause the airways in the lungs to narrow and swell, and they can also cause allergy symptoms. By blocking the leukotrienes, montelukast improves asthma symptoms, helps control asthma, and improves symptoms of seasonal allergies (also known as hay fever or seasonal allergic rhinitis).
When to Use Montelukast Aurovitas
Your doctor has prescribed montelukast to treat asthma and prevent asthma symptoms during the day and night.
Depending on your symptoms and the severity of your asthma, your doctor will determine how you should use Montelukast Aurovitas.
What is Asthma?
Asthma is a chronic disease.
Asthma includes:
The symptoms of asthma include: Cough, wheezing, and chest congestion.
What are Seasonal Allergies?
Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an allergic response often caused by airborne pollen from trees, grass, and weeds. Symptoms of seasonal allergies typically include: stuffy nose, runny nose; sneezing; itchy, watery, swollen, red, and painful eyes.
Tell your doctor about any allergy or medical problem you have now or have had.
Do not take Montelukast Aurovitas
Warnings and Precautions
Consult your doctor or pharmacist before starting Montelukast Aurovitas.
Several neuropsychiatric events (such as changes in behavior and mood-related, depression, and suicidal tendencies) have been reported in patients of all ages treated with montelukast (see section 4). If you develop these symptoms while taking montelukast, you should contact your doctor. |
Children and Adolescents
Do not give this medicine to children under 15 years of age.
For pediatric patients under 18 years of age, other formulations of this medicine are available based on the age range.
Taking Montelukast Aurovitas with Other Medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Some medicines may affect the way montelukast works, or montelukast may affect the way other medicines work.
Before taking Montelukast, tell your doctor if you are taking the following medicines:
Taking Montelukast Aurovitas with Food and Drinks
Montelukast Aurovitas can be taken with or without food.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Your doctor will assess whether you can take montelukast during this period.
Breastfeeding
It is not known whether montelukast passes into breast milk. If you are breastfeeding or plan to breastfeed, consult your doctor before taking Montelukast Aurovitas.
Driving and Using Machines
Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to the medicine may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with montelukast may affect your ability to drive or operate machinery.
Montelukast Aurovitas Contains Lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Montelukast Aurovitas Contains Sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
For Adults and Adolescents 15 Years of Age and Older:
The recommended dose is one 10 mg tablet daily in the evening.
If you are taking Montelukast Aurovitas, make sure you do not take any other product containing the same active ingredient, montelukast.
This medicine is taken orally.
Montelukast Aurovitas can be taken with or without food.
If You Take More Montelukast Aurovitas Than You Should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (telephone: 91 562 04 20) indicating the medicine and the amount ingested.
In most cases of overdose, no adverse effects were reported. The symptoms that occurred most frequently reported in overdose in adults and children were abdominal pain, drowsiness, thirst, headache, vomiting, and hyperactivity.
If You Forget to Take Montelukast Aurovitas
Try to take Montelukast Aurovitas as prescribed. However, if you miss a dose, just resume your regular schedule of one tablet once daily.
Do not take a double dose to make up for forgotten doses.
If You Stop Taking Montelukast Aurovitas
Montelukast Aurovitas will only treat your asthma if you continue taking it.
It is essential that you continue taking Montelukast Aurovitas for the time your doctor prescribes. It will help control your asthma.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In clinical trials conducted with montelukast 10 mg film-coated tablets, the side effects related to the administration of Montelukast Aurovitas and reported most frequently (may affect up to 1 in 10 people) were:
These side effects were generally mild and occurred with a higher frequency in patients treated with montelukast than with placebo (a pill that does not contain medicine).
Serious Side Effects
Consult your doctor immediatelyif you observe any of the following side effects, as they may be serious and may require urgent medical treatment.
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very Rare (may affect up to 1 in 10,000 people):
Other Side Effects Reported During the Marketing of the Medicinal Product
Very Common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very Rare (may affect up to 1 in 10,000 people):
Reporting of Side Effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines and Healthcare Products Agency (AEMPS) through the website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton/label/bottle after EXP. The expiry date is the last day of the month stated.
Store below 25°C.
Store in the original package to protect from light and moisture.
Use within 30 days of first opening the PEAD bottle.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Montelukast Aurovitas
Core of the tablet: lactose monohydrate, microcrystalline cellulose (E 460), sodium croscarmellose, hydroxypropylcellulose (E 463), magnesium stearate (E 572).
Coating: hydroxypropylcellulose (E 463), hypromellose 6cp (E 464), titanium dioxide (E 171), yellow iron oxide (E 172), carnauba wax (E 903), red iron oxide (E 172).
Appearance of the Product and Contents of the Pack
Film-Coated Tablets
Film-coated tablets of beige color, square shape with rounded edges, marked with "X" on one face and "54" on the other face of the tablet.
Blister packs of Polyamide / Aluminum foil / PVC - Aluminum foil
Package sizes: 7, 10, 14, 20, 28, 30, 49, 50, 56, 60, 84, 90, 98, 100, 140, and 200 tablets.
High-density polyethylene (PEAD) bottles with a polypropylene cap containing silica gel desiccant
Package sizes: 30 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far,
Birzebbugia, BBG 3000.
Malta
This medicine is authorized in the Member States of the European Economic Area under the following names:
France MONTELUKAST ARROW 10 mg, film-coated tablet
Germany Montelukast Aurobindo 10 mg Filmtabletten
Ireland MONTELUKAST 10 mg Film-Coated Tablets
Italy Montelukast Aurobindo 10mg film-coated tablets
Malta Montelukast Aurobindo 10mg film-coated tablets
Netherlands Montelukast Aurobindo 10 mg, film-coated tablets
Poland Montelukast Aurovitas
Spain Montelukast Aurovitas 10 mg film-coated tablets EFG
Date of the Last Revision of this Leaflet: February 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es/)
The average price of MONTELUKAST AUROVITAS 10 mg FILM-COATED TABLETS in November, 2025 is around 21.06 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MONTELUKAST AUROVITAS 10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.